MYD88 mutations are expressed in Waldenstrom Macroglobulinaemia (WM) (95-97%), immune-privileged lymphomas (50-80%), activated B-cell (ABC) subtype of diffuse large Bcell lymphoma (DLBCL) (15-30%), marginal zone lymphoma (6-10%) and chronic lymphocytic leukaemia (CLL) (3-8%) (Montesinos-Rongeri et al, 2011; Ngo et al, 2011; Pasqualucci et al, 2011; Puente et al, 2011; Treon et al, 2012; Mart ınez et al, 2014) . In WM, nearly all cases express the MYD88 L265P mutation (Treon et al, 2012) ; 50-80% of IgM
MGUS patients express MYD88
L265P by allele-specific polymerase chain reaction, and its expression is associated with an increased risk of malignant progression Xu et al, 2013) . The importance of mutated MYD88 in supporting tumour cell survival in ABC DLBCL and WM was established by MYD88 gene knock-down and/or over-expression studies (Ngo et al, 2011; Treon et al, 2012; Yang et al, 2013) . MYD88 dimerization is necessary for assembly of the Myddosome, a structure composed of MYD88 dimers that recruit and activate interleukin-1 receptor-associated kinase (IRAK) 4, which in turn recruits and activates IRAK1 or 2. The MYD88:IRAK4:IRAK1/2 complex can then trigger canonical nuclear factor-kappa B (NFjB) growth and survival signalling (Ngo et al, 2011; Yang et al, 2013) . The Myddosome can also activate Bruton Tyrosine Kinase (BTK), which can promote canonical NFjB signalling in mutated MYD88 WM cells (Lin et al, 2010) . In contrast to native MYD88, mutated MYD88 protein can assemble without external stimuli, and trigger constitutive NFjB activation (Ngo et al, 2011; Treon et al, 2012; Yang et al, 2013 295-302 transduced BCWM.1 cells (Fig 2B) . A potential scaffold function for the IRAK proteins may also explain why knockdown of IRAK1 or IRAK4 produces higher levels of apoptosis than observed with inhibitors targeting these kinases in MYD88 mutated WM cells (Yang et al, , 2015 Lastly, the findings also provide regions of interest that are conducive to the development of small molecules, peptidomimetics or stapled peptides for potential therapeutic application. Larger peptide sequences (>8-mers) may be needed within the TIR MYD88 181-202 domain to achieve sustained growth suppression as observed in our studies. The development of stapled peptides may be particularly suitable, as longer (20-mer peptides) have been developed for therapeutic application by this approach (Walensky & Bird, 2014) . In addition, the MYD88 181-202 domain has an alpha helical configuration that is ideal for manufacturing stapled peptides (Fig 1B) . It is also possible that multiple stapled peptides targeting both the TIR and DD domains could be used to more optimally block Myddosome assembly. In summary, we show that interference of Myddosome assembly within select regions of the TIR and DD domains can impact growth and survival signalling of MYD88 L265P mutated WM cells. Our findings provide a framework for developing agents that interfere with Myddosome assembly in WM, and possibly for other lymphoproliferative disorders driven by MYD88-activating mutations.
